topical BRAF inhibitor (gel) for EGFRi rash Ph. I in mCRC with EGFRi-related rash paradoxical activ. of MAPK to counter EGFRi Cancer Discovery, May 25, 2021 Lutris-Parma, Tel Aviv, IL / MSKCC, NY